Evidence map›Paper›PMID 34596721›Full record

ReviewApplied microbiology and biotechnology2021

Probiotics as potential therapeutic options for Alzheimer's disease.

Hong-Fang Ji, Liang Shen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Effects ofNutrients · 2022
    Trial
  3. Review
  4. Review
  5. Antioxidants (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Microorganisms · 2025
    Article
  10. Selenium-EnrichedAntioxidants (Basel, Switzerland) · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Early-Life Environment Influence on Late-Onset Alzheimer's Disease.Frontiers in cell and developmental biology · 2022
    Review
  15. Article
  16. Review
  17. Selenium Nanoparticles-EnrichedInternational journal of nanomedicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hong-Fang JiInstitute of Biomedical Research, Shandong University of Technology, Zibo, Shandong, People's Republic of China. jhf@sdut.edu.cn.ORCID http://orcid.org/0000-0002-4855-3590
Liang ShenInstitute of Biomedical Research, Shandong University of Technology, Zibo, Shandong, People's Republic of China. shen@sdut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The steadily increasing prevalence of Alzheimer's disease (AD) worldwide and the lack of effective therapeutic agent attract novel therapeutic approach in recent years. In view of the close relationships between gut microbiota and AD, probiotics have been suggested as potential therapeutic options for AD in recent years. The present review discussed the research progresses concerning the effects of probiotics administration to combat AD. A total of 35 studies, including 26 animal model studies and 9 human studies, were included herein. Among the 26 animal model studies, 24 used mice model, and 2 used Caenorhabditis elegans and Drosophila melanogaster AD models, respectively. As for probiotics, a total of 13 studies employed single-strain probiotic, and the rest studies used multi-strain probiotics (ranged from 2 to 9 probiotic strains), 4 used probiotic-fermented milk or probiotic-fermented soybean, 2 studies used engineered probiotic strain, and 4 studies focused on the combined effect of probiotics with AD drug memantine, selenium, or exercise. Bifidobacterium and Lactobacillus species were the most frequently used probiotics in the included studies. Overall, currently available studies showed that probiotic administration conferred neuroprotective benefits and could attenuate cognitive deficits and modulate gut microbiota dysbiosis, which may be related to oxidative and inflammatory pathways. Several perspectives on future studies on this topic are proposed. Thus, probiotics seem to be an attractive approach to combat AD, which deserves to be further studied by well-designed large-scale clinical studies. KEY POINTS: •We discussed the recent progresses concerning the effects of probiotics administration to combat AD. •A total of 35 associated studies consisted of 26 animal model studies and 9 human studies were included. •Most studies found that probiotic administration conferred neuroprotective benefits and could attenuate cognitive deficits.

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeProbioticsAnimalsBifidobacteriumDrosophila melanogasterMiceAlzheimer’s diseaseGut microbiotaProbiotics

Identifiers

PMID34596721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.